Pfizer Stock Stuck or Set for a Comeback?

​

On May 4, 2026, Pfizer Inc. remains in focus as Pfizer stock continues to trade sluggishly, raising questions about its future direction. The spotlight is firmly on whether Pfizer stock can regain momentum.

Pfizer Stock: Waiting Game or Hidden Potential?

ETF Inflows Power Bitcoin Rally

Pfizer stock is still down over 50% from its 2021 high, reflecting the sharp drop in COVID vaccine demand and mounting challenges, including upcoming patent expirations that could weigh on revenue.

Still, Pfizer is not standing still. The company has accelerated efforts in the weight-loss segment, securing new assets and partnerships tied to GLP-1 treatments. “Every setback sets the stage for a comeback.”

Income Appeal Amid Uncertainty

Compared to Eli Lilly, which benefits from booming demand, Pfizer stock stands out for income investors. Its dividend yield is about 6.4%, versus roughly 0.6% for Eli Lilly.

Management remains committed to sustaining payouts while advancing drug pipelines. For now, Pfizer stock reflects a balance between near-term pressure and long-term promise.